All India Institute of Medical Sciences (AIIMS) director Dr. Randeep Guleria said that Bharat Biotech’s Covid-19 vaccine, Covaxin, is likely to be approved for children by September.
As per the report, he said that after the completion of the second and third phase of trials of COVID-19 vaccine Covaxin for children, the trial data would be made available by September. The vaccine is likely to be approved in the same month, Dr. Guleria said.
He further said that if the Pfizer-BioNTech shot would be approved in India, it could be another alternative for children to be vaccinated with.
According to the experts, a potential third Covid-19 wave will be particularly hard-hitting on children. Thus, Covaxin is being trialed in children, aged between 2 and 17, at AIIMS Delhi and Patna.
On May 12, the Drugs Controller General of India (DCGI) approved Bharat Biotech’s permission to conduct phase 2 and 3 trials for children.
Meanwhile, Dr Randeep Guleria has disagreed that children will be particularly impacted by a third wave. He said that there was “no reason to believe this theory.”
It was in line with a recent AIIMS-World Health Organization (WHO) report which stated that the third wave “may not hit children disproportionately.”
Click here to follow PTC News on Twitter